

**Supplemental Table 2.** Comparison of the baseline clinicopathological characteristics between the development and validation sets

Variables	Development set (n=153)	Validation set (n=73)	P-value
Age, years, median(range)	52 (17-80)	55 (28-79)	0.96
Sex, Male, no. (%)	130 (85.0)	56 (76.7)	0.13
Etiology, no. (%)			
HBV	135 (88.2)	63 (86.3)	0.58
HCV	9 (5.9)	6 (8.2)	
Alcohol	6 (3.9)	0 (0.0)	
Others	3 (2.0)	4 (5.5)	
Child-Pugh class, no. (%)			
A	141 (92.2)	70 (95.9)	0.40
B	12 (7.8)	3 (4.1)	
Serum alpha fetoprotein, no. (%)			
>400 ng/mL	55 (35.9)	22 (30.1)	0.39
Intrahepatic HCC morphology, no. (%)			
Nodular type	149 (97.4)	71 (97.3)	1.00
Infiltrative type	4 (2.6)	2 (2.7)	
AJCC T stage, no. (%)			
1	108 (70.6)	49 (67.1)	0.36
2	32 (20.9)	14 (19.2)	
3	13 (8.5)	10 (13.7)	
Portal vein invasion, no. (%)	5 (3.3)	9 (12.3)	0.02
Edmondson-Steiner grade, no. (%)			
I	5 (3.3)	1 (1.4)	< 0.01
II	47 (31.1)	52 (71.2)	
III	87 (57.6)	18 (24.7)	
IV	12 (7.9)	2 (2.7)	

FGFR, fibroblast growth factor receptor; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AJCC, American Joint Committee on Cancer.